Role of BMP Pathway in MDS Progression

Launched by HOSPICES CIVILS DE LYON · Dec 8, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating the role of a specific biological pathway called the Bone Morphogenetic Protein (BMP) pathway in the progression of myelodysplastic syndromes (MDS), which are blood disorders that can develop into a more severe condition known as acute myelogenous leukemia (AML). The researchers believe that changes in the BMP pathway could be linked to how MDS evolves into AML. By studying this pathway, they hope to find new ways to prevent or treat the transformation from MDS to AML.

To participate in this study, adults who have been diagnosed with MDS or who are suspected of having MDS may be eligible. This also includes adults who are suspected of having newly diagnosed AML at the start of treatment. However, people with certain other blood disorders or those who have already received specific treatments for MDS or AML may not be able to join. The trial is not yet recruiting participants, but once it begins, those who take part can expect to contribute to important research that could lead to better treatments for these serious conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization Or
• • Adult patient with suspicion of de novo acute myeloid leukemia at initial treatment
• Exclusion Criteria:
• • Frontier MDS/myeloproliferative syndromes including chronic myelomonocytic leukemia
• • MDS and AML having already benefited from cytotoxic treatment including hydroxycarbamide, azacytidine, intensive chemotherapy
• • Patients objecting to their inclusion in the study
• • Pregnant or breastfeeding women
• • Patients under legal protection measure